Acarbose - search results

Australia - English - Department of Health (Therapeutic Goods Administration)

acarbose viatris acarbose 100 mg tablet blister pack

arrotex pharmaceuticals pty ltd - acarbose, quantity: 100 mg - tablet - excipient ingredients: colloidal anhydrous silica; pregelatinised maize starch; microcrystalline cellulose; magnesium stearate - as an adjunct to prescribed diet and exercise for the management of blood glucose concentrations in non-insulin dependent diabetic patients who are inadequately controlled by diet alone or by diet and oral hypoglycaemic agents.

Australia - English - Department of Health (Therapeutic Goods Administration)

acarbose viatris acarbose 50 mg tablet blister pack

arrotex pharmaceuticals pty ltd - acarbose, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; pregelatinised maize starch; microcrystalline cellulose; colloidal anhydrous silica - as an adjunct to prescribed diet and exercise for the management of blood glucose concentrations in non-insulin dependent diabetic patients who are inadequately controlled by diet alone or by diet and oral hypoglycaemic agents.

Canada - English - Health Canada

mar-acarbose tablet

marcan pharmaceuticals inc - acarbose - tablet - 50mg - acarbose 50mg - alpha-glucosidase inhibitors

Canada - English - Health Canada

mar-acarbose tablet

marcan pharmaceuticals inc - acarbose - tablet - 100mg - acarbose 100mg - alpha-glucosidase inhibitors

United States - English - NLM (National Library of Medicine)

acarbose- acarbose tablet

pd-rx pharmaceuticals, inc. - acarbose (unii: t58msi464g) (acarbose - unii:t58msi464g) - acarbose 50 mg - acarbose tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. acarbose tablets are contraindicated in patients with known hypersensitivity to the drug. acarbose tablets are also contraindicated in patients with diabetic ketoacidosis or cirrhosis. acarbose tablets are also contraindicated in patients with inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or in patients predisposed to intestinal obstruction. in addition, acarbose tablets are contraindicated in patients who have chronic intestinal diseases associated with marked disorders of digestion or absorption and in patients who have conditions that may deteriorate as a result of increased gas formation in the intestine.